Chimerix (NASDAQ:CMRX – Get Free Report) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23), Zacks reports. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $1.26 million. During the same period in the prior year, the business posted ($0.21) earnings per share.
Chimerix Stock Up 2.2 %
Chimerix stock traded up $0.02 during mid-day trading on Thursday, reaching $0.86. 407,001 shares of the company’s stock traded hands, compared to its average volume of 320,351. Chimerix has a 12-month low of $0.75 and a 12-month high of $1.30. The company has a market cap of $77.28 million, a price-to-earnings ratio of -0.89 and a beta of 1.20. The stock has a 50 day moving average of $0.88 and a two-hundred day moving average of $0.97.
Analyst Ratings Changes
A number of equities analysts recently weighed in on CMRX shares. StockNews.com lowered shares of Chimerix from a “hold” rating to a “sell” rating in a research report on Tuesday. Wedbush restated an “outperform” rating and set a $6.00 target price on shares of Chimerix in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Wednesday.
About Chimerix
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Featured Articles
- Five stocks we like better than Chimerix
- What is a buyback in stocks? A comprehensive guide for investors
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What is the Nikkei 225 index?
- Jeff Brown’s Exegesis AI Stock Picks
- Buy P&G Now, Before It Sets A New All-Time High
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.
